IP Verse

Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis - EP3351246

The patent EP3351246 was granted to Novartis on Sep 18, 2019. The application was originally filed on Feb 18, 2002 under application number EP18155644A. The patent is currently recorded with a legal status of "Revoked".

EP3351246

NOVARTIS
Application Number
EP18155644A
Filing Date
Feb 18, 2002
Status
Revoked
Oct 23, 2023
Grant Date
Sep 18, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ARROW GENERIQUESFeb 24, 2020TRIPOZADMISSIBLE
TEVA PHARMACEUTICALSFeb 22, 2020AUGUST DEBOUZYADMISSIBLE
GENERICS UKFeb 21, 2020ELKINGTON AND FIFEADMISSIBLE
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELJan 29, 2020MAIWALDADMISSIBLE
ZENTIVA PHARMASep 16, 2019BIRD & BIRDADMISSIBLE
ACCORD HEALTHCAREJul 31, 2019PLOUGMANN VINGTOFTWITHDRAWN
ETHYPHARMJul 3, 2019LLRADMISSIBLE
BIOGARANJul 1, 2019CASALONGAADMISSIBLE
STADA ARZNEIMITTELMay 23, 2019HAMM & WITTKOPPADMISSIBLE

Patent Citations (65) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0296110
DESCRIPTIONEP0520722
DESCRIPTIONEP0564409
DESCRIPTIONEP0566226
DESCRIPTIONEP0769947
DESCRIPTIONEP0787722
DESCRIPTIONEP0837063
DESCRIPTIONGB2177700
DESCRIPTIONUS4100274
DESCRIPTIONUS4636505
DESCRIPTIONUS4659516
DESCRIPTIONUS5010099
DESCRIPTIONUS5362718
DESCRIPTIONUS5747498
DESCRIPTIONUS5843901
DESCRIPTIONWO0009495
DESCRIPTIONWO0027819
DESCRIPTIONWO0027820
DESCRIPTIONWO0037502
DESCRIPTIONWO0059509
DESCRIPTIONWO9409010
DESCRIPTIONWO9410202
DESCRIPTIONWO9503283
DESCRIPTIONWO9516691
DESCRIPTIONWO9630347
DESCRIPTIONWO9633980
DESCRIPTIONWO9641807
DESCRIPTIONWO9702266
DESCRIPTIONWO9730034
DESCRIPTIONWO9738983
DESCRIPTIONWO9749688
DESCRIPTIONWO9810767
DESCRIPTIONWO9811223
DESCRIPTIONWO9835958
DESCRIPTIONWO9903854
DESCRIPTIONWO9917804
EXAMINATIONUS5206018
OPPOSITIONEP0663916
OPPOSITIONEP1363267
OPPOSITIONEP2269603
OPPOSITIONEP2783686
OPPOSITIONEP3143995
OPPOSITIONEP3406249
OPPOSITIONGB104072
OPPOSITIONGB124957
OPPOSITIONGB2177700
OPPOSITIONUS5066493
OPPOSITIONUS5206018
OPPOSITIONUS5922730
OPPOSITIONWO0069467
OPPOSITIONWO0112633
OPPOSITIONWO0151049
OPPOSITIONWO0164193
OPPOSITIONWO02066019
OPPOSITIONWO02080975
OPPOSITIONWO9409010
OPPOSITIONWO9747317
OTHEREP1363627
OTHEREP3406249
OTHERWO0069467
OTHERWO02066019
OTHERWO9747317
SEARCHWO0151049
SEARCHWO9409010
SEARCHWO9747317

Non-Patent Literature (NPL) Citations (117) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CLARK, Breast Cancer Research Treatment, (19970000), vol. 46, page 255-
DESCRIPTION- F. YUAN et al., Proc. Natl. Acad. Sci. USA, (19961200), vol. 93, pages 14765 - 14770-
DESCRIPTION- J. MORDENTI et al., Toxicologic Pathology, (19990000), vol. 27, no. 1, pages 14 - 21-
DESCRIPTION- M. PREWETT et al., Cancer Research, (19990000), vol. 59, pages 5209 - 5218-
DESCRIPTION- M. S. O'REILLY et al., Cell, (19940000), vol. 79, pages 315 - 328-
DESCRIPTION- M. S. O'REILLY et al., Cell, (19970000), vol. 88, pages 277 - 285-
DESCRIPTION- Z. ZHU et al., Cancer Res., (19980000), vol. 58, pages 3209 - 3214-
EXAMINATION- BUZDAR A ET AL, "Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20010901), vol. 7, no. 9, ISSN 1078-0432, pages 2620 - 2635, XP002784456-
EXAMINATION- CLEMETT DELYTH ET AL, "Exemestane: A review of its use in postmenopausal women with advanced breast cancer", DRUGS, ADIS INTERNATIONAL LTD, NZ, (20000601), vol. 59, no. 6, ISSN 0012-6667, pages 1279 - 1296, XP002784405-
EXAMINATION- GOSS P E ET AL, "Aromatase inhibitors in the treatment and prevention of breast cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, (20010201), vol. 19, no. 3, ISSN 0732-183X, pages 881 - 894, XP003022842-
EXAMINATION- TSUCHIYA N ET AL, "EFFECTS OF FADROZOLE AND LEUPRORELIN ACETATE ON AROMATASE ACTIVITY AND CELL PROLIFERATION IN A HUMAN BREAST CANCER CELL LINE (SK-BR-3)", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, CHURCHILL LIVINGSTONE JAPAN, TOKYO, GB, (20000101), vol. 5, ISSN 1341-9625, pages 183 - 187, XP001069645-
EXAMINATION- YU K ET AL, "MTOR, A NOVEL TARGET IN BREAST CANCER: THE EFFECT OF CCI-779, AN MTOR INHIBITOR, IN PRECLINICAL MODELS OF BREAST CANCER", ENDOCRINE - RELATED CANCER, BIOSCIENTIFICA LTD, GB, (20010901), vol. 8, no. 3, doi:10.1677/ERC.0.0080249, ISSN 1351-0088, pages 249 - 258, XP001079023
OPPOSITION- ADAMS et al., "Vascular Endothelial Growth Factor (VEGF) in Breast Cancer: Comparison of Plasma, Serum, and Tissue VEGF and Microvessel Density and Effects of Tamoxifen1", Cancer Res., (20000000), vol. 60, pages 2898 - 2905, XP055717952-
OPPOSITION- "AROMASIN® (exemestane) Tablets", FDA Label, (19991020), XP055545079-
OPPOSITION- "AROMASIN® ( exemestane) Tablets", FDA label on Aromasin Tabletts, (19991020), pages 1 - 13, XP055545079-
OPPOSITION- "Aromatase inhibitor", Wikipedia, (20151226), URL: https://en.wikipedia.org/w/index.php?title=Aromatase_inhibitor&oldid=696884780, XP055717893-
OPPOSITION- AUERBACH, R. et al., "Angiogenesis assays: Problems and pitfalls", Cancer and Metastasis Reviews, (20000000), vol. 19, pages 167 - 172, XP055695232-
OPPOSITION- BAJETTA et al., "AROMATASE INHIBITORS IN THE TREATMENT OF POSTMENOPAUSAL BREAST CANCER", Drugs & Aging, (19991000), vol. 15, no. 4, pages 271 - 283, XP008007766-
OPPOSITION- BEUVINK, "Antitumor Activity of RAD001, an Orally Active Rapamycin Derivative", Proc Am Assoc Cancer Research, (20010300), XP001093826-
OPPOSITION- BEUVINK et al., "#1972 Antitumor Activity of RAD001, an Orally Active Rapamycin Derivative", Proceedings of the American Association for Cancer Research, (20010300), vol. 42, page 366, XP001093826-
OPPOSITION- BEUVINK et al., "1972 Antitumor Activity of RAD001, an Orally Active Repamycin Derivative", Proc. Am. Ass. Cancer Research, (20010300), vol. 42, page 366, XP055621157-
OPPOSITION- BEUVINK et al., "1972 Antitumor Activity of RAD001, an Orally Active Repamycin Derivative", Proceedings of the American Association for Cancer research, (20010000), vol. 42, XP055621157-
OPPOSITION- BEUVINK et al., "Abstract 1972: Antitumor activity of RAD001, an orally active rapamycin derivative", Proc Am Assoc Cancer Res, (20010000), vol. 42, page 366, XP055545109-
OPPOSITION- BEUVINK et al., "Abstract 1972: Antitumor activity of RAD001, an orally active rapamycin derivative", Proceedings of the American Association for Cancer Research, (20010300), vol. 42, page 366, XP055545109-
OPPOSITION- BUZDAR, "Advances in Aromatase Inhibition: Clinical Efficacy and Tolerability in the Treatment of Breast Cancer", Clinical Cancer Research, (20010900), vol. 7, no. 9, pages 2620 - 2635, XP002784456-
OPPOSITION- BUZDAR et al., "Advances in aromatase inhibition : clinical efficacy and tolerability in the treatment of breast cancer", Clinical Cancer Research, (20010000), vol. 7, pages 2620 - 2635, XP002784456-
OPPOSITION- BUZDAR et al., "Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer", Clinical Cancer Research, (20010900), vol. 7, pages 2620 - 2635, XP002784456-
OPPOSITION- "CHMP assessment report for Afinitor", EMEA/533232/2009, (20090529), pages 1 - 75, URL: https://www.ema.europa.eu/en/documents/assessment-report/afinitor-epar-public-assessment-report_en.pdf, XP055695905-
OPPOSITION- DUMONT, "Everolimus Novartis", Current Opinion in Investigational Drugs, (20010000), vol. 2, pages 1220 - 1234, XP055639440-
OPPOSITION- DUMONT, F. J . et al., "Everolimus, Novartis", Current Opinion in Investigational Drugs, (20010000), vol. 2, no. 9, pages 1220 - 1234, XP055639440-
OPPOSITION- DUMONT FJ, "Everolimus, Novartis", Curr. Opin. Investig. Drugs, (20010900), vol. 2, no. 9, pages 1220 - 34, XP055639440-
OPPOSITION- EMA, "Assessment report Afinitor everolimus", EMA/723893/2011, (20110902), pages 1 - 54, URL: https://www.ema.europa.eu/en/documents/variation-report/afinitor-h-c-1038-ii-0008-epar-assessment-report-variation_en.pdf, XP055695908-
OPPOSITION- Ema, "Assessment report Afinitor everolimus", EMA/CHMP/438808/2012, (20120621), pages 1 - 79, URL: https://www.ema.europa.eu/en/documents/variation-report/afinitor-h-c-1038-ii-0020-epar-assessment-report-variation_en.pdf, XP055695910-
OPPOSITION- EMA, "Extension of indication variation assessment report Afinitor: Everolimus", EMA/390543/2016, (20160428), pages 1 - 80, XP055695918-
OPPOSITION- EMA, "Public summary of opinion on orphan designation Everolimus for the treatment of gastric cancer", EMA/COMP/546609/2011 Rev.2, (20150204), pages 1 - 4, URL: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/11/894-public-summary-opinion-orphan-designation-everolimus-treatment-gastric-cancer_en.pdf, XP055695879-
OPPOSITION- EMA, "Public summary of opinion on orphan designation Everolimus for the treatment of renal cell carcinoma", EMA/COMP/202020/2007 Rev.3, (20150204), URL: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/07/449-public-summary-positive-opinion-orphan-designation-everolimus-treatment-renal-cell-carcinoma_en.pdf, XP055695883-
OPPOSITION- ENG et al., "ACTIVITY OF RAPAMYCIN (AY-22,989) AGAINST TRANSPLANTED TUMORS", Journal of Antibiotics, (19840000), vol. 37, pages 1231 - 1237, XP001095310-
OPPOSITION- FABIAN, C.J., "The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer", Int. J. Clin. Prac., (20071200), vol. 61, no. 12, pages 2051 - 2063, XP02530212-
OPPOSITION- FRANKE et al., "PI3K: Downstream AKTion Minireview Blocks Apoptosis", Cell, (19970000), vol. 88, pages 435 - 437, XP055717896-
OPPOSITION- Haiyan Pang, "Steroids, rapamycin and breast cancer cells", Dissertation Medical College of Ohio, (2001), XP055717945-
OPPOSITION- HOFFMANN, "Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic", Investigational New Drugs, (19991100), vol. 17, no. 4, pages 343 - 359, XP055640217-
OPPOSITION- HOSOI et al., "RAPAMYCIN CAUSES POORLY REVERSIBLE INHIBITION OF MTOR AND INDUCES P53-INDEPENDENT APOPTOSIS IN HUMAN RHABBOMYOSARCOMA CELLS", Cancer Res., (19990000), vol. 59, pages 886 - 894, XP001154916-
OPPOSITION- HOSOI, H. et al., "Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells", Cancer Res., (19990215), vol. 59, no. 4, pages 886 - 94, XP001154916-
OPPOSITION- ILAN et al., "Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis", J Cell Sci, (19980000), vol. 111, pages 3621 - 3631, XP055717962-
OPPOSITION- KAUFMANN et al., "Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial", J. of Clinical Oncology, (20000000), vol. 18, pages 1399 - 1411, XP002176335-
OPPOSITION- Leaflet of Aromasin®, (201507), pages 1 - 5, XP055645641-
OPPOSITION- LONNING et al., "ACTIVITY OF EXEMESTANE IN METASTATIC BREAST CANCER AFTER FAILURE OF NONSTEROIDAL AROMATASE INHIBITORS: A PHASE II TRIAL", In J. Clin. Oncol., (20000600), vol. 18, no. 11, pages 2234 - 2244, XP001034132-
OPPOSITION- MC MAHON et al., "High-throughput analysis of everolimus (RADOOl) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system", Rapid Commun. Mass Spectrom., (20000928), vol. 14, no. 21, pages 1965 - 1971, XP055639343-
OPPOSITION- NHS, "Improving outcomes in breast cancer", Guidance on Cancer Services. Manual update, (20020828), URL: https://www.nice.org.uk/guidance/csg1/resources/improving-outcomes-in-breast-cancer-update-pdf-773371117, XP055695798-
OPPOSITION- "Novartis drug Afinitor® helps women with advanced breast cancer live significantly longer without their disease progressing", Novartis press release, (20110926), XP055545090-
OPPOSITION- Pharmacia & Upjon S P A, "Aromasin-exemestane", FDA label, (19991020), pages 1 - 13, XP055545079-
OPPOSITION- Public Health England - cell collection HCT116-
OPPOSITION- SANTEN R.J. et al., "Use of aromatase inhibitors in breast cancer", Endocrine-Related Cancer, (19990300), vol. 6, no. 1, pages 75 - 92, XP055695825-
OPPOSITION- ZHONG et al., "MODULATION OF HYPOXIA-INDUCIBLE FACTOR 1ALPHA EXPRESSION BY THE EPIDERMAL GROWTH FACTOR-PHOSPHATIDYLINOSITOL 3-KINASE/PTEN/AKT/FRAPPATHWAY IN HUMAN PROSTATE CANCER CELLS: IMPLICATIONS FOR TUMOR ANGIOGENESIS AND THERAPEUTICS", Cancer Res, (20000000), vol. 60, pages 1541 - 1545, XP002931192-
OPPOSITION- ZHONG et al., "MODULATION OF HYPOXIA-INDUCIBLE FACTOR 1ALPHA EXPRESSION BY THE EPIDERMAL GROWTH FACTOR-PHOSPHATIDYLINOSITOL 3-KINASE/PTEN/AKT/FRAPPATHWAY IN HUMAN PROSTATE CANCER CELLS: IMPLICATIONS FOR TUMOR ANGIOGENESIS AND THERAPEUTICS", Cancer Research, (20000000), vol. 60, pages 1541 - 1545, XP002931192-
OPPOSITION- GUBA et al., "Chirurgisches forum 2001 für experimentelle und klinische Forschung", Rapamycin inhibits tumor growth and metastasis by antiangiogenesis, (20010000), pages 37 - 39, XP001088707
OPPOSITION- GUBA et al., "RAPAMYCIN INHIBIERT DAS TUMORWACHTSUM UND DIE TUMORMETASTASIERUNG UEBER ANTIANGIOGENESE//RAPAMYCIN INHIBITS TUMOR GROWTH AND METASTASIS BY ANTIANGIOGENESIS", Chirurgisches Forum, (20010000), vol. 30, pages 37 - 39, XP001088707
OPPOSITION- GUBA M. et al., "Rapamycin inhibiert das Tumorwachstum und die Tumormetastasierung über Antiangiogenese Authors Authors and affiliations", Chirurgisches Forum 2001 für experimentelle und klinische Forschung, (20010500), vol. 30, pages 37 - 39, XP001088707
OPPOSITION- TSUCHIYA et al., "Effects of fadrozole and leuprorelin acetate on aromatase activity and cell proliferation in a human breast cancer cell line (SK-BR-3)", Int. J Clin Oncol, (20000000), vol. 5, no. 3, doi:10.1007/PL00012035, ISSN 1341-9625, pages 183 - 187, XP055271005
OPPOSITION- CONWAY E M; COLLEN D; CARMELIET P, "Molecular mechanisms of blood vessel growth", Cardiovascular Research, (20010000), vol. 49, pages 507 - 521, XP002978423
OPPOSITION- SEDRANI et al., "CHEMICAL MODIFICATION OF RAPAMYCIN: THE DISCOVERY OF SDZ RAD", Transplantation Proceedings, (19980000), vol. 30, pages 2192 - 2194, XP000925138
OPPOSITION- SEDRANI, R., "Chemical modification of rapamycin: the discovery of SDZ RAD", Transplant Proc, (19980000), vol. 30, no. 5, doi:10.1016/S0041-1345(98)00587-9, pages 2192 - 4, XP000925138
OPPOSITION- SCHMELZLE et al., "TOR, a central controller of cell growth", Cell, (20000000), vol. 103, pages 253 - 262, XP002297034
OPPOSITION- SHU Y-Z, "RECENT NATURAL PRODUCTS BASED DRUG DEVELOPMENT: A PHARMACEUTICAL INDUSTRY PERSPECTIVE", RECENT NATURAL PRODUCTS BASED DRUG DEVELOPMENT: A PHARMACEUTICAL INDUSTRY PERSPECTIVE Journal of natural products, (19980000), vol. 61, pages 1053 - 1071, XP001120005
OPPOSITION- HAIYAN PANG et al., "Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells", Breast Cancer Research and Treatment, (20011100), vol. 70, no. 1, doi:10.1023/A:1012570204923, ISSN 0167-6806, pages 21 - 26, XP055622864
OPPOSITION- SEMENZA, "HIF-1: Using Two Hands to Flip the Angiogenic Switch", Cancer and Metastasis Reviews, (20000000), vol. 19, pages 59 - 65, XP055717968
OPPOSITION- SIMONCINI, "INTERACTION OF OESTROGEN RECEPTOR WITH THE REGULATORY SUBUNIT OF PHOSPHATIDYLINOSITOL-3-OH KINASE", Nature, (20000000), vol. 407, pages 538 - 541, XP001008835
OPPOSITION- BLUME-JENSEN et al., "ONCOGENIC KINASE SIGNALLING", Nature, (20010000), vol. 411, pages 355 - 365, XP001156920
OPPOSITION- BROWN et al., "A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX", Nature, (19940000), vol. 369, pages 756 - 758, XP002031997
OPPOSITION- HIDALGO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogen, (20000000), vol. 19, no. 56, doi:10.1038/sj.onc.1204091, ISSN 0950-9232, pages 6680 - 6696, XP009002368
OPPOSITION- HIDALGO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (19990000), vol. 19, pages 6680 - 6686, XP002323912
OPPOSITION- HIDALGO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20001227), vol. 19, no. 56, pages 6680 - 6686, XP002323912
OPPOSITION- HIDALGO, M. et al., "The rapamycin sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20000000), doi:10.1038/sj.onc.1204091, pages 6680 - 6686, XP009002368
OPPOSITION- MENDE et al., "Oncogenic transformation induced by membrane-targeted Akt2 and Akt3", Oncogene, (20010000), vol. 20, pages 4419 - 4423, XP002299908
OPPOSITION- NEUHAUS et al., "mTOR Inhibitors: An Overview", Liver Transplantation, (20010000), vol. 7, pages 473 - 484, XP055542856
OPPOSITION- NEUHAUS et al., "mTOR Inhibitors: An Overview", Liver Transplantation, (20010600), vol. 7, no. 6, pages 473 - 484, XP055542856
OPPOSITION- HUANG et al., "MECHANISMS OF RESISTANCE TO RAPAMYCINS", Drug Resistance Updates, (20010000), vol. 4, pages 378 - 392, XP001094520
OPPOSITION- HUANG et al., "MECHANISMS OF RESISTANCE TO RAPAMYCINS", Drug Resistance Updates, (20011200), vol. 4, no. 6, pages 378 - 391, XP001094520
OPPOSITION- HUANG, S. et al., "Mechanisms of resistance to rapamycins", Drug Resist Updat., (20011200), vol. 4, no. 6, doi:10.1054/drup.2002.0227, pages 378 - 91, XP001094520
OPPOSITION- RAUGHT et al., "The Target of Rapamycin (TOR) proteins", PNAS, (20010000), vol. 98, pages 7037 - 7044, XP002228993
OPPOSITION- MILLS et al., "Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo", PNAS, (20010000), vol. 98, pages 10031 - 10033, XP002379746
OPPOSITION- AOKI et al., "A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt", PNAS, (20010000), vol. 98, pages 136 - 141, XP055271133
OPPOSITION- SCHUURMAN H-J et al., "SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Synergism with Cyclosporine", Transplantation, (19970715), vol. 64, no. 1, pages 32 - 35, XP002048030
OPPOSITION- SCHULER et al., "SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo", Transplantation, (19970715), vol. 64, no. 1, pages 36 - 24, XP002048032
OPPOSITION- S CHULER et al., "SDZ RAD, a new rapamycin derivative", Transplantation, (19970000), vol. 64, pages 36 - 42, XP002048032
OPPOSITION- SCHULER et al., "SDZ RAD, A NEW RAPAMYCIN DERIVATIVE", Transplantation, (19970000), vol. 64, pages 36 - 42, XP002048032
OPPOSITION- SCHULER, W., "SDZ RAD, A New Rapamycin Derivative", Transplantation, (19970000), vol. 64, doi:10.1097/00007890-199707150-00008, pages 36 - 42, XP002048032
OPPOSITION- C.J. Fabian, "The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer", Int. J. Clin. Prac., (20071200), vol. 61, no. 12, pages 2051 - 2063, XP002530212
OPPOSITION- FABIAN, "The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer", International Journal of Clinical Practice, (20071200), vol. 61, pages 2051 - 2063, XP002530212
OPPOSITION- HEITMAN et al., "TARGETS FOR CELL CYCLE ARREST BY THE IMMUNOSUPPRESSANT RAPAMYCIN IN YEAST", Science, (19910000), vol. 253, pages 905 - 909, XP008041458
OPPOSITION- FRY, "Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?", Breast Cancer Res, (20010000), vol. 3, no. 5, pages 304 - 312, XP055717895
OPPOSITION- Simpson and Davis, "Minireview: Aromatase and the regulation of estrogen biosynthesis - some new perspectives", Endocrinology, (20011100), vol. 142, no. 11, pages 4589 - 4594, XP055270898
OPPOSITION- SIMPSON et al., "Minireview: aromatase and the regulation of estrogen biosynthesis--some new perspectives", Endocrinology, (20010000), vol. 142, no. 11, pages 4589 - 4594, XP055270898
OPPOSITION- POLITI et al., "First symposium of novel molecular targets for cancer therapy", The Oncologist, (20010000), vol. 6, pages 207 - 212, XP055717905
OPPOSITION- K YU et al., "MTOR, A NOVEL TARGET IN BREAST CANCER: THE EFFECT OF CCI-779, AN MTOR INHIBITOR, IN PRECLINICAL MODELS OF BREAST CANCER", Endocr. Relat. Cance r, (20010900), vol. 8, no. 3, pages 249 - 258, XP001079023
OPPOSITION- YU et al., "mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.", Endocrine related cancer, (20010000), vol. 8, no. 3, page 249258, XP001079023
OPPOSITION- YU et al., "MTOR, A NOVEL TARGET IN BREAST CANCER: THE EFFECT OF CCI-779, AN MTOR INHIBITOR, IN PRECLINICAL MODELS OF BREAST CANCER", Endocrine-Related Cancer, (20010900), vol. 8, no. 3, pages 249 - 258, XP001079023
OPPOSITION- YU et al., "MTOR, A NOVEL TARGET IN BREAST CANCER: THE EFFECT OF CCI-779, AN MTOR INHIBITOR, IN PRECLINICAL MODELS OF BREAST CANCER", Endocrine-Related Cancer, (20010900), vol. 8, pages 249 - 258, XP001079023
OPPOSITION- YU K, ET AL., "MTOR, A NOVEL TARGET IN BREAST CANCER: THE EFFECT OF CCI-779, AN MTOR INHIBITOR, IN PRECLINICAL MODELS OF BREAST CANCER", Endocrine - Related Cancer, BioScientifica Ltd., GB, GB, (20010901), vol. 08, no. 03, doi:10.1677/erc.0.0080249, ISSN 1351-0088, pages 249 - 258, XP001079023
OPPOSITION- YU, K. et al., "mTOR, a novel target in breast cancer: the effect of CCI-77, an mTOR inhibitor, in preclinical models of breast cancer", Endocrine-Related Cancer, (20010908), doi:10.1677/erc.0.0080249, pages 249 - 258, XP001079023
OPPOSITION- NJAR et al., "COMPREHENSIVE PHARMACOLOGY AND CLINICAL EFFICACY OF AROMATASE INHIBITORS", Drugs, (19990800), vol. 58, no. 2, pages 233 - 255, XP001104959
OPPOSITION- SCOTT et al., "Exemestane", Drugs, (19990000), vol. 58, no. 4, doi:10.2165/00003495-199958040-00007, pages 675 - 680, XP001104951
OPPOSITION- SCOTT et al., "Exemestane", Drugs, (19991000), vol. 58, no. 4, pages 675 - 680, XP001104951
OPPOSITION- SCOTT, L. J. et al., "Exemestane", Adis New Drug Profile, Drugs, (19990000), vol. 58, no. 4, doi:10.2165/00003495-199958040-00007, pages 675 - 680, XP001104951
OPPOSITION- CRUCITTA et al., "Current Issue Early Online Most Read Most Cited (Dimensions) Most Cited (CrossRef) Social Media Archive Information Online Submission Information for Authors Language Editing Information for Reviewers Editorial Policies Editorial Academy Aims and Scope Abstracting and Indexing Bibliographic Information Information for Librarians Information for Advertisers Reprints and permissions Contact the Editor General Information About Spandidos Conferences Job Opportunities Contact Terms and Conditions New aromatase inhibitors in the treatment of advanced breast cancer", Int. Journal of Oncology, (20001100), vol. 17, no. 5, pages 1037 - 1041, XP055695820
OTHER- Anonymous, "Antiestrogen", Wikipedia, the free encyclopedia, (20180330), pages 1 - 2, XP055545064-
OTHER- Anonymous, "Aromatase inhibitor", Wikipedia, the free encyclopedia, (20181104), pages 1 - 6, XP055545081-
OTHER- Beukink I., Et Al, "Abstract 1972: Antitumor activity of RAD001, an orally active rapamycin derivative", Proceedings of the American Association for Cancer Research, vol. 42, (20110301), XP055545109-
OTHER- Novartis, "Novartis drug Afinitor® helps women with advanced breast cancer live significantly longer without their disease progressing", NOVARTIS Press Release, (20111126), XP055545090-
OTHER- Pharmacia & Upjon S.P.A., "AROMASIN® ( exemestane) Tablets", FDA Label, (19991020), pages 1 - 13, XP055545079-
SEARCH- HIDALGO M ET AL, "A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", ANNALS OF ONCOL, KLUWER, DORDRECHT, NL, (2000), vol. 11, no. Suppl. 4, ISSN 0923-7534, page 133, XP009193116 [A] 1-9 * abstract *-
SEARCH- HIDALGO M ET AL, "CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY, THE SOCIETY, US, (2000), vol. 19, ISSN 1081-0641, page 187, XP009193117 [A] 1-9 * abstract *-
SEARCH- SEUFFERLEIN THOMAS ET AL, "Rapamycin inhibits constitutive p70-s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells", CANCER RESEARCH, AACR - AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (1996), vol. 56, no. 17, ISSN 0008-5472, pages 3895 - 3897, XP002766076 [A] 1-9 * abstract *-
SEARCH- SHAH SHIMUL A ET AL, "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, (20001102), vol. 97, no. 2, doi:10.1006/JSRE.2001.6145, ISSN 0022-4804, pages 123 - 130, XP029590080 [A] 1-9 * abstract *
SEARCH- GUBA M ET AL, "RAPAMYCIN INHIBIERT DAS TUMORWACHTSUM UND DIE TUMORMETASTASIERUNG UEBER ANTIANGIOGENESE//RAPAMYCIN INHIBITS TUMOR GROWTH AND METASTASIS BY ANTIANGIOGENESIS", CHIRURGISCHES FORUM FUER EXPERIMENTELLE UND KLINISCHE FORSCHUNG, BERLIN, DE, (20010101), ISSN 0303-6227, pages 37 - 39, XP001088707 [I] 1-9 * the whole document *
SEARCH- SEUFFERLEIN T ET AL, "Constitutive activation of p70s6k in human pancreatic cancer cell lines bearing activating Ki-ras mutations", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 114, doi:10.1016/S0016-5085(98)82012-X, ISSN 0016-5085, (19980415), page A496, (19980415), XP027466913 [A] 1-9 * abstract *
SEARCH- HIDALGO M ET AL, "THE RAPAMYCIN-SENSITIVE SIGNAL TRANSDUCTION PATHWAY AS A TARGET FOR CANCER THERAPY", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, (200012), vol. 19, no. 56, doi:10.1038/SJ.ONC.1204091, ISSN 0950-9232, pages 6680 - 6686, XP009002368 [A] 1-9 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents